Key findings: CagriSema achieved up to 23% weight loss at 84 weeks Tirzepatide showed numerical superiority (~25.5%) The trial did not meet non-inferiority vs tirzepatide Clinical interpretation: Despite not meeting the primary endpoint, an important signal emerges: targeting multiple biological pathways remains a compelling strategy Why this matters: Reinforces obesity as a complex neuroendocrine disease Supports the concept that multi-hormonal approaches may better impact the defended weight set point Moves the field closer to precision, mechanism-based therapies Safety: Consistent with the GLP-1 class Mainly gastrointestinal adverse events, generally mild to moderate and transient Whats next: Ongoing development with higher-dose CagriSema Expansion of the REDEFINE program FDA decision expected by late 2026 Take-home message: The future of obesity treatment lies not in a single pathway, but in strategically combining mechanisms to sustainably shift weight biology
78 Another meta-analysis that included three trials using a standardized red clover isoflavone extract (Promensil) at a dose of 80 mg per day found a significant hot flash-reducing effect
Notably, levels returned to baseline after a 1-month washout period, indicating that continuous supplementation is required to maintain elevated levels
Understanding these terms is the first step in ensuring your treatment remains safe and effective
MeloAPSDippenaarINJohnsonSCWeaverNDde Assis AcurcioFMaltaDCet alAll-cause and cause-specific mortality among people with severe mental illness in Brazils public health system, 2000-15: a retrospective study
Preclinical in vitro and in vivo studies indicate that GLP-1RA treatment does not exacerbate cancer risk in patients with type 2 diabetes and concurrent pancreatic cancer [13]
